CoChat

Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells

Baird, J. Kevin, Dewi, Mewahyu, Subekti, Decy, Elyazar, Iqbal, Satyagraha, Ari W. · 2015 · Translational Research
Cited by 31

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trsl.2014.09.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 36

  1. Gething, 2012, A long neglected world malaria map: Plasmodium vivax endemicity in 2010, PLoS Negl Trop Dis, 6, e1814, 10.1371/journal.pntd.0001814 · DOI · Paper page
  2. Price, 2007, Vivax malaria: neglected and not benign, Am J Trop Med Hyg, 77, 79, 10.4269/ajtmh.2007.77.79 · DOI · Paper page
  3. Anstey, 2012, Plasmodium vivax: risk factors and pathogenesis, Adv Parasitol, 80, 151, 10.1016/B978-0-12-397900-1.00003-7 · DOI · Paper page
  4. von Seidlein, 2013, Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report, Malar J, 12, 112, 10.1186/1475-2875-12-112 · DOI · Paper page
  5. White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malar J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page
  6. Eyles, 1948, The parasitological pattern of relapsing Plasmodium vivax in military patients, J Natl Malar Soc, 7, 23
  7. Pukrittayakamee, 2000, Therapeutic responses to different antimalarial drugs in vivax malaria, Antimicrob Agents Chemother, 44, 1680, 10.1128/AAC.44.6.1680-1685.2000 · DOI · Paper page
  8. Sutanto, 2013, Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia, Antimicrob Agents Chemother, 57, 1128, 10.1128/AAC.01879-12 · DOI
  9. Douglas, 2011, Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics, Clin Infect Dis, 52, 612, 10.1093/cid/ciq249 · DOI · Paper page
  10. Baird, 2002, Seasonal malaria attack rates in infants and young children in northern Ghana, Am J Trop Med Hyg, 66, 280, 10.4269/ajtmh.2002.66.280 · DOI · Paper page
  11. Baird, 2012, Diagnosis and treatment of Plasmodium vivax malaria, Adv Parasitol, 80, 203, 10.1016/B978-0-12-397900-1.00004-9 · DOI
  12. Beutler, 1954, The hemolytic effect of primaquine. III. A study of primaquine-sensitive erythrocytes, J Lab Clin Med, 44, 177
  13. Beutler, 2007, Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development, Am J Trop Med Hyg, 77, 779, 10.4269/ajtmh.2007.77.779 · DOI · Paper page
  14. Clark, 2009, Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility, Eur J Hum Genet, 17, 1080, 10.1038/ejhg.2009.8 · DOI · Paper page
  15. Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map, PLoS Med, 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
  16. Beutler, 2008, Glucose-6-phosphate dehydrogenase: a historical perspective, Blood, 111, 16, 10.1182/blood-2007-04-077412 · DOI · Paper page
  17. Beutler, 1966, A series of new screening procedures for pyruvate kinase deficiency, glucose-6-phosphate dehydrogenase deficiency, and glutathione reductase deficiency, Blood, 28, 553, 10.1182/blood.V28.4.553.553 · DOI
  18. Boulard, 1972, The effect of copper ion on red cell enzyme activities, J Clin Invest, 51, 459, 10.1172/JCI106833 · doi:10.1172/jci106833
  19. Beutler, 1994, G6PD deficiency, Blood, 84, 3613, 10.1182/blood.V84.11.3613.bloodjournal84113613 · DOI · Paper page
  20. Filosa, 1996, Somatic cell selection is a major determinant of the blood cell phenotype in heterozygotes for glucose-6-phosphate dehydrogenase mutations causing severe enzyme deficiency, Am J Hum Genet, 59, 887
  21. Kim, 2011, Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening, PLoS One, 6, e28357, 10.1371/journal.pone.0028357 · DOI · Paper page
  22. da Silva, 2008, Methods for equivalence and noninferiority testing, Biol Blood Marrow Transplant, 15, 120
  23. Wolf, 1987, Detection of glucose-6-phosphate dehydrogenase deficiency in erythrocytes: a spectrophotometric assay and fluorescent spot test compared with a cytochemical method, Clin Chim Acta, 168, 129, 10.1016/0009-8981(87)90281-6 · doi:10.1016/0009-8981(87)90281-6
  24. Wong, 2009, Comparison of detection of glucose-6-phosphate dehydrogenase deficiency using fluorescent spot test, enzyme assay, and molecular method for prediction of severe neonatal hyperbilirubinemia, Singapore Med J, 50, 62
  25. Clyde, 1981, Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug, Bull World Health Organ, 59, 391
  26. Salvidio, 1967, Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians, N Engl J Med, 276, 1339, 10.1056/NEJM196706152762402 · doi:10.1056/nejm196706152762402
  27. Pannacciulli, 1965, The course of experimentally induced hemolytic anemia in a primaquine-sensitive Caucasian: a case study, Blood, 25, 92, 10.1182/blood.V25.1.92.92 · DOI · Paper page
  28. George, 1967, Primaquine sensitivity in Caucasians: hemolytic reactions induced by primaquine in G6PD deficient subjects, J Lab Clin Med, 70, 80
  29. Alving, 1960, Mitigation of the haemolytic effect of primaquine and enhancement of its against the exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report, Bull World Health Organ, 22, 621
  30. Peters, 2009, Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women, J Histochem Cytochem, 57, 1003, 10.1369/jhc.2009.953828 · DOI
  31. Howes, 2013, Spatial distribution of G6PD deficiency variants across malaria-endemic regions, Malar J, 12, 418, 10.1186/1475-2875-12-418 · DOI · Paper page
  32. Loucharoen, 2009, Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians, Science, 326, 1546, 10.1126/science.1178849 · DOI · Paper page
  33. Baird, 2004, Primaquine therapy for malaria, Clin Infect Dis, 39, 1336, 10.1086/424663 · DOI · Paper page
  34. John, 2012, Primaquine radical cure of Plasmodium vivax: a critical review of the literature, Malar J, 11, 280, 10.1186/1475-2875-11-280 · DOI · Paper page
  35. Durand, 2014, Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax in the Amazon Basin of Peru, Am J Trop Med Hyg, 91, 18, 10.4269/ajtmh.13-0053 · doi:10.4269/ajtmh.13-0053
  36. Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria, N Engl J Med, 369, 1381, 10.1056/NEJMc1301936 · DOI · Paper page

Cited by

See all 31

Metadata

Authors
Baird, J. K., Dewi, M., Subekti, D., Elyazar, I., & Satyagraha, A. W.
Venue
Translational Research
Publisher
Elsevier BV
Published
2015-06
Volume
165
Issue
6
Pages
677-688
ISSN
1931-5244
Cited by
31
References
3
Language
en
Licence
Funders
Wellcome Trust (B9RJIXO)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.